Ox-LDL诱导肝硬化患者巨噬细胞产生ET

肝脏 ›› 2019, Vol. 24 ›› Issue (9): 1007-1010.

Ox-LDL诱导肝硬化患者巨噬细胞产生ET

孟庆洋, 徐春林, 康鹏

150086 哈尔滨医科大学附属第二医院感染科

收稿日期:2019-06-19 发布日期:2020-04-15
通讯作者: 康鹏,Email:kangpeng19761231@163.com

Ox-LDL-induced ETs production of macrophages in patients with cirrhosis

MENG Qing-yang, XU Chun-lin, KANG Peng

Department of Infectious Disease, the Second Affiliated Hospital of Harbin Medical University, Harbin 150086, China

Received:2019-06-19 Published:2020-04-15
Contact: KANG Peng, Email: kangpeng19761231@163.com

摘要/Abstract

摘要： 目的探讨氧化低密度脂蛋白(oxidized low-density lipoprotein,ox-LDL)诱导肝硬化患者巨噬细胞形成胞外诱捕网(ET)对肝硬化发展的作用。方法运用肝脏超声及肝脏弹性成像检测筛选肝硬化患者;通过ox-LDL等不同物质刺激巨噬细胞,观察ET的形成;检测ox-LDL、ET水平;诱导巨噬细胞表型转换。结果 Ox-LDL刺激健康人巨噬细胞无ET产生;Ox-LDL可诱导肝硬化患者巨噬细胞形成ET,且在刺激后5 h达到峰值;ET诱导巨噬细胞表型M1向表型M2转化。结论 ox-LDL可诱导肝硬化患者巨噬细胞产生ET,可能与肝硬化发展机制有关。

关键词: 细胞外诱捕网, 巨噬细胞, 肝硬化, 氧化低密度脂蛋白

Abstract: Objective To investigate whether the oxidized low-density lipoprotein (ox-LDL) in cirrhosis patients induces macrophages to release extracellular traps (ETs) and promotes the development of cirrhosis.Methods Liver ultrasound and transient elastography were used to screen patients with cirrhosis. The formation of ETs was observed by stimulating macrophages with ox-LDL and other substances. Ox-LDL and ETs levels were detected. Phenotype transformation of macrophages was induced.Results Macrophages in healthy people did not release ETs with the stimulation of ox-LDL. Conversely, the ETs formation of macrophages in patients with cirrhosis was induced by the stimulation of ox-LDL, which reached its peak at 5 hours after stimulation. ETs induced the transformation of macrophages from phenotype M1 to M2.Conclusion Ox-LDL can induce macrophages to produce ETs in patients with cirrhosis, which may be related to the development mechanism of cirrhosis.

Key words: Extracellular traps, Macrophages, Liver cirrhosis, Oxidized low-density lipoprotein

孟庆洋, 徐春林, 康鹏. Ox-LDL诱导肝硬化患者巨噬细胞产生ET[J]. 肝脏, 2019, 24(9): 1007-1010.

MENG Qing-yang, XU Chun-lin, KANG Peng. Ox-LDL-induced ETs production of macrophages in patients with cirrhosis[J]. Chinese Hepatolgy, 2019, 24(9): 1007-1010.

参考文献

[1] Guimaraes-Costa AB, Nascimento MT, Wardini AB, et al. ETosis: a microbicidal mechanism beyond cell death.J ParasitolRes,2012,2012:929743.
[2] Remijsen Q, Kuijpers TW, Wirawan E, et al. Dying for a cause: NETosis, mechanisms behind an antimicrobial cell death modality.Cell Death?Differ,2011,18:581-588.
[3] Duewell P, Kono H, Rayner KJ, et al. NLRP3 inflamasomes are required for atherogenesis and activated by cholesterol crystals that form early in disease.Nature,2010,464:1357-1361.
[4] Wartha F, Beiter K, Normark S, et al. Neutrophil extracellular traps: casting the NET over pathogenesis.Curr Opin Microbiol,2007,10:52-56.
[5] Bruns S, Kniemeyer O, Hasenberg M, et al. Production of extracellular traps against Aspergillus fumigatus in vitro and in infected lung tissue is dependent on invading neutrophils and influenced by hydrophobin RodA.PLoS Pathog,2010,6:e1000873.
[6] Ermert D, Urban C F, Laube B, et al. Mouse neutrophil extracellular traps in microbial infections. J Innate Immun,2009,1:181-193.
[7] Berger-Achituv S, Brinkmann V, Abu-Abed U, et al. A proposed role for neutrophil extracellular traps in cancer immunoediting.Front Immunol,2013,6;4:48.
[8] Kessenbrock K, Krumbholz M, Schnermarck U, et al. Netting neutrophils in autoimmune small-vessel vasculitis.Nat Med,2009,15:623-625.
[9] Yu Y, Su K. Neutrophil extracellular traps and systemic lupus erythematosus.J Clin Cell Immunol,2013,4,pii:139.
[10] Liu Y, Liu S, Cai Y, et al. Effects of combined aerobic and resistance training on the glycolipid metabolism and inflammation levels in type 2 diabetes mellitus.J Phys Ther Sci,2015,27:2365-2371.
[11] Nian X, Zhang X, Wang Y, et al. Correlations of FOXC2 gene expression and polymorphism with type 2 diabetes mellitus. Clin Lab, 2016, 62: 781-791.
[12] Cahn A, Cernea S, Raz I. An update on DPP-4 inhibitors in the management of type 2 diabetes.Expert Opin Emerg Drugs,2016,21:409-419.
[13] Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria.Science,2004,303:1532-1535.

[1]	陈艳, 林瑞, 陈竹, 王丽. 2012至2018年某院肝硬化并自发性细菌性腹膜炎的病原学及耐药性分析[J]. 肝脏, 2020, 25(2): 166-168.
[2]	郇稳, 史丽璞. 干燥综合征合并原发性胆汁性肝硬化患者的外周血Th17/Treg细胞百分比及临床特征[J]. 肝脏, 2020, 25(2): 155-157.
[3]	孔媛媛, 魏巍, 单姗, 马红, 欧晓娟, 徐小元, 段钟平, 侯金林, 魏来, 尤红, 贾继东, 中国消除乙肝临床科研平台(CR-HepB)研究组. 乙型肝炎肝硬化患者的临床特征与抗病毒治疗模式变化[J]. 肝脏, 2020, 25(2): 123-127.
[4]	薛超, 马文娜, 孙庆文, 李冲杰. 脐带间充质干细胞治疗失代偿期肝硬化12例临床疗效观察[J]. 肝脏, 2020, 25(1): 66-68.
[5]	李松, 张娟. 替诺福韦酯对乙型肝炎肝硬化患者肝纤维化状态与Th1/Th2型细胞因子的影响研究[J]. 肝脏, 2020, 25(1): 54-55.
[6]	赵开飞, 谭瑞, 蒋国军, 石荣书, 韦鑫佩, 杜松丽. 脾动脉支架限流术治疗肝硬化门静脉高压的实验研究[J]. 肝脏, 2019, 24(9): 1019-1021.
[7]	张学秀, 姚建宁, 张延祯, 李艳乐, 王春峰, 张连峰. ¹³C-美沙西丁呼气试验在原发性胆汁性胆管炎中的临床应用[J]. 肝脏, 2019, 24(9): 1025-1028.
[8]	刘晓超, 何创业. 特利加压素治疗失代偿期肝硬化合并肝肾综合征患者的量效关系[J]. 肝脏, 2019, 24(9): 1034-1037.
[9]	刘薇, 袁海霞, 时强. 抗病毒治疗慢性乙型肝炎肝硬化后肝纤维化逆转情况观察[J]. 肝脏, 2019, 24(9): 1055-1057.
[10]	徐强, 马燕, 郭峰, 王晓波, 王晓忠. 肝硬化相关急性肾损伤30天内死亡的相关因素分析[J]. 肝脏, 2019, 24(8): 857-860.
[11]	钱嵘, 杨唯衷. 经颅多普勒超声结合屏气试验评价肝硬化患者大脑中动脉血流动力学改变[J]. 肝脏, 2019, 24(8): 861-863.
[12]	陆伟, 刘丹萍, 张占卿, 王雁冰, 丁荣蓉, 周新兰, 黄丹, 李秀芬, 杨可芷. APRI、GPR和FIB-4预测抗病毒诱导的乙型肝炎肝硬化肝脏病理学回归的性能评价[J]. 肝脏, 2019, 24(8): 875-882.
[13]	魏玮, 相芳. 卡维地洛对肝硬化伴顽固性腹水患者门静脉血流动力学和存活质量的影响[J]. 肝脏, 2019, 24(8): 883-886.
[14]	江强, 李珍, 甘海忠. 慢性乙型肝炎肝硬化患者并发肾功能衰竭的预测模型建立及研究[J]. 肝脏, 2019, 24(8): 886-890.
[15]	杨帆, 程黎娜, 张玲娟, 李修岭. TIPS用于肝硬化门脉高压对患者远期预后的影响[J]. 肝脏, 2019, 24(8): 893-895.